Small adenocarcinoma of the lung: Prognostic significance of central fibrosis chiefly because of its association with angiogenesis and lymphangiogenesis

Pathology International

Volumn 56, Issue 9, 2006, Pages 494-502

  Okudera, Koichi ^a   Kamata, Yoshimasa ^a   Takanashi, Shingo ^a   Hasegawa, Yukihiro ^a   Tsushima, Takao ^a   Ogura, Yuta ^b   Nakanishi, Kuniaki ^c   Sato, Hiroshi ^d   Okumura, Ken ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b AOMORI ROSAI HOSPITAL   (Japan)

^c NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^d KANAZAWA UNIVERSITY   (Japan)

Author keywords

Adenocarcinoma; Extracellular matrix; Fibrosis; Immunohistochemistry; In situ hybridization; Lung; Lymphangiogenesis; Neovascularization; Prognosis

Indexed keywords

CD34 ANTIGEN; GELATINASE A; MATRIX METALLOPROTEINASE 14; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER SURVIVAL; CARCINOMA CELL; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG ADENOCARCINOMA; LUNG FIBROSIS; LYMPH VESSEL; LYMPHANGIOGENESIS; MALE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SMALL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG NEOPLASMS; LYMPHANGIOGENESIS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASES; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PULMONARY FIBROSIS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 33747453022     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2006.01997.x     Document Type: Article

References (44)

1. Shimosato Y, Suzuki A, Hashimoto T et al. Prognostic implications of fibrotic focus (scar) in small peripheral lung cancers. Am J Surg Pathol 1980; 4: 365-73.
2. Kurokawa T, Matsuno Y, Noguchi M, Mizuno S, Shimosato Y. Surgically curable 'early' adenocarcinoma in the periphery of the lung. Am J Surg Pathol 1994; 18: 431-8.
3. Noguchi M, Morikawa A, Kawasaki M et al. Small adenocarcinoma of the lung: Histologic characteristics and prognosis. Cancer 1995; 75: 2844-52.
4. Suzuki K, Yokose T, Yoshida J et al. Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Ann Thorac Surg 2000; 69: 893-7.
5. Maeshima AM, Niki T, Maeshima A, Yamada T, Kondo H, Matsuno Y. Modified scar grade: A prognostic indicator in small peripheral lung adenocarcinoma. Cancer 2002; 95: 2546-54.
6. Sobin LH, Wittekind Ch, eds. TNM Classification of Malignant Tumours, 6th edn. New York: Wiley-Liss, 2002.
7. Nakanishi K, Kawai T, Sato H et al. Expression of matrix metalloproteinase-2 (MMP-2) and of membrane-type-1-matrix metalloproteinase (MT1-MMP) in transitional cell carcinoma of the upper urinary tract. Hum Pathol 2000; 31: 193-200.
8. Yamamura T, Nakanishi K, Hiroi S et al. Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in nonsmall cell lung carcinomas. Lung Cancer 2002; 35: 249-55.
9. Weidner N, Semple JP, Welch WR et al. Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
10. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147: 9-19.
11. Dazzi C, Cariello A, Maioli P et al. Prognostic and predictive value of intratumoral microvessels density in operable nonsmall-cell lung cancer. Lung Cancer 1999; 24: 81-8.
12. Fontanini G, Bigini D, Vignati S et al. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol 1995; 177: 57-63.
13. Yamazaki K, Abe S, Takekawa H et al. Tumor angiogenesis in human lung adenocarcinoma. Cancer 1994; 74: 2245-50.
14. Koukourakis MI, Giatromanolaki A, Sivridis E et al. LYVE-1 immunohistochemical assessment of lymphangiogenesis in endometrial and lung cancer. J Clin Pathol 2005; 58: 202-6.
15. Colby TV, Noguchi M, Henschke C et al. Adenocarcinoma. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004; 35-44.
16. Ishiwa N, Ogawa N, Shoji A et al. Correlation between lymph node micrometastasis and histologic classification of small lung adenocarcinoma, in considering the indication of limited surgery. Lung Cancer 2003; 39: 159-64.
17. Yokose T, Suzuki K, Nagai K, Nishiwaki Y, Sasaki S, Ochiai A. Favorable and unfavorable morphological prognostic factors in peripheral adenocarcinoma of the lung 3 cm or less in diameter. Lung Cancer 2000; 29: 179-88.
18. Terasaki H, Niki T, Matsuno Y et al. Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: Clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am J Surg Pathol 2003; 27: 937-51.
19. Takise A, Kodama T, Shimosato Y, Watanabe S, Suemasu K. Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter. Cancer 1988; 61: 2083-8.
20. Yamashiro K, Yasuda S, Nagase A, Hirata T, Nojima T, Nagashima K. Prognostic significance of an interface pattern of central fibrosis and tumor cells in peripheral adenocarcinoma of the lung. Hum Pathol 1995; 26: 67-73.
21. Sakurai H, Maeshima A, Watanabe S et al. Grade of stromal invasion in small adenocarcinoma of the lung: Histopathological minimal invasion and prognosis. Am J Surg Pathol 2004; 28: 198-206.
22. Webb T. Lymphangiogenesis explored as potential route for metastasis. JNCI 2001; 93: 498-9.
23. Suzuki M, Iizasa T, Fujisawa T et al. Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small-cell lung cancer. Invasion Metastasis 1998/99; 18: 134-41.
24. Kitamura H, Oosawa Y, Kawano N et al. Basement membrane patterns, gelatinase A and tissue inhibitor of metalloproteinase-2 expressions, and stromal fibrosis during the development of peripheral lung adenocarcinoma. Hum Pathol 1999; 30: 331-8.
25. Kumaki F, Matsui K, Kawai T et al. Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia. Am J Pathol 2001; 159: 2125-35.
26. Sato H, Takino T, Miyamori H. Roles of membrane-type matrix metalloproteinase-1 in tumor invasion and metastasis. Cancer Sci 2005; 96: 212-17.
27. Passlick B, Sienel W, Seen-Hibler R et al. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res 2000; 6: 3944-8.
28. Iijima T, Minami Y, Nakamura N et al. MMP-2 activation and stepwise progression of pulmonary adenocarcinoma: Analysis of MMP-2 and MMP-9 with gelatin zymography. Pathol Int 2004; 54: 295-301.
29. Nawrocki B, Polette M, Marchand V et al. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: Quantificative and morphological analyses. Int J Cancer 1997; 72: 556-64.
30. Polette M, Nawrocki B, Gilles C et al. MT-MMP expression and localisation in human lung and breast cancers. Virchows Arch 1996; 428: 29-35.
31. Ishikawa S, Takenaka K, Yanagihara K et al. Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer. Clin Cancer Res 2004; 10: 6579-85.
32. Fina L, Molgaard HV, Robertson D et al. Expression of the CD34 gene in vascular endothelial cells. Blood 1990; 75: 2417-26.
33. Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 2005; 115: 849-60.
34. Offersen BV, Pfeiffer P, Hamilton-Dutoit S, Overgaard J. Patterns of angiogenesis in nonsmall-cell lung carcinoma. Cancer 2001; 91: 1500-9.
35. Passalidou E, Trivella M, Singh N et al. Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br J Cancer 2002; 86: 244-9.
36. Pezzella F, Pastorino U, Tagliabue E et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 1997; 151: 1417-23.
37. Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K. Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 2001; 91: 964-71.
38. Masuya D, Huang C, Liu D et al. The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients. Cancer 2001; 92: 2628-38.
39. Giatromanolaki A. Prognostic role of angiogenesis in non-small cell lung cancer. Anticancer Res 2001; 21: 4373-82.
40. Stacker SA, Baldwin ME, Achen MG. The role of tumor lymphangiogenesis in metastatic spread. FASEB J 2002; 16: 922-34.
41. Clarijs R, Ruiter DJ, de Waal RM. Lymphangiogenesis in malignant tumours: Does it occur? J Pathol 2001; 193: 143-6.
42. Dadras SS, Paul T, Bertoncini J et al. Tumor lymphangiogenesis: A novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003; 162: 1951-60.
43. Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 2002; 82: 1255-7.
44. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol 2002; 15: 434-40.